Bristol Myers Squibb
Q2 2023 Earnings Call
Jul 27, 2023, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good morning, everyone. Welcome to the Bristol-Myers Squibb second quarter 2023 earnings conference call. All participants will be in a listen-only mode. [Operator instructions] Please also note, today's event is being recorded.
At this time, I'd like to turn the floor over to Tim Power, vice president of investor relations. Mr. Power, please go ahead.
Tim Power -- Vice President, Investor Relations
Thank you. Good morning, everyone, and thanks for joining us this morning for our second quarter 2023 earnings call. Joining me this morning with prepared remarks are Giovanni Caforio, our board chair and chief executive officer; and David Elkins, our chief financial officer. Also participating in today's call are Chris Boerner, our chief operating officer; Adam Lenkowsky, our chief commercialization officer; and Samit Hirawat, our chief medical officer and head of global drug development.
As you'll note, we've posted slides to BMS.com that you can follow along with for Giovanni and David's remarks. Before we get started, I'll read our forward-looking statement. During this call, we'll make statements about the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the company's SEC filings.
These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date. We specifically disclaim any obligation to update forward-looking statements even if our estimates change. We'll also focus our comments on our non-GAAP financial measures, which are adjusted to exclude certain specified items. Reconciliations of certain non-GAAP financial measures to the most comparable GAAP measures are available at bms.com.
With that, I'll hand it over to Giovanni.
Giovanni Caforio -- Chairman and Chief Executive Officer
Thank you, Tim, and good morning, everyone. Starting on Slide 4, as you will have seen in our press release this morning, today we updated our outlook for 2023. The updates were driven by a significant change in our expectations for Revlimid, and to a lesser extent, Pomalyst for the year. Let me say that we do not take an adjustment of this magnitude lightly.